1093.HK vs 2269.HK: Side-by-Side Comparison
Compare CSPC Pharmaceutical Group Limited (1093.HK) and WuXi Biologics (Cayman) Inc. (2269.HK) side by side: market cap HKD 79.50B vs HKD 142.15B, P/E 17.9 vs 25.8. Financials, growth and model signals on Bullrun.
| Metric | 1093.HK | 2269.HK |
|---|---|---|
| Company | CSPC Pharmaceutical Group Limited | WuXi Biologics (Cayman) Inc. |
| Country / Exchange | Hong Kong | Hong Kong |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Market cap | HKD 79.50B | HKD 142.15B |
| P/E ratio | 17.9 | 25.8 |
| Dividend yield | 4.20% | — |
| Valuation model | — | — |
| Revenue (FY2025) | HKD 26.01B | HKD 21.79B |
| Revenue growth YoY | -10.4% | +16.7% |
| Net income | HKD 3.88B | HKD 4.91B |
| Gross margin | 65.6% | 46.0% |
| Diluted EPS | 0.34 | 1.16 |